M42’s Tawam Molecular Imaging Centre and Mubadala Health Dubai partner with Re:Cognition Health (UK) to expand access to specialist memory and brain health services in Dubai and Al Ain
• Re:Cognition Health has launched its first regional clinical service at Mubadala Health Dubai, with a second phase planned at Tawam Molecular Imaging Centers in Al Ain.
• The collaboration will connect patients with specialist assessment, advanced imaging, diagnostic testing, and treatment for memory, cognitive, neurodegenerative, and neurodevelopmental conditions.
Abu Dhabi, UAE – October 22, 2026 – M42’s Mubadala Health Dubai (MHD) and Tawam Molecular Imaging Centre (TMIC) have partnered with UK-based Re:Cognition Health to expand access to specialized memory and brain health services across the UAE. The first phase has launched at MHD in Dubai, with services at TMIC in Al Ain to follow.
Signed during the Abu Dhabi Future Health Summit (ADFHS), the agreement marks Re:Cognition Health’s first clinical presence in the region. It brings the organization’s expertise in memory, cognitive, neurodegenerative and neurodevelopmental conditions into M42’s multidisciplinary clinical and imaging network, creating a coordinated route from initial assessment to diagnosis, treatment and follow-up care.
Re:Cognition Health will contribute clinical expertise in memory and brain health, advanced diagnostic approaches, neurodevelopmental assessment and treatment pathways for Alzheimer’s disease and related conditions.
For eligible patients with early Alzheimer’s disease, treatments may include disease-modifying therapies, subject to clinical assessment, applicable regulatory requirements and established eligibility criteria. Patients receiving these treatments will benefit from specialist oversight and appropriate safety monitoring throughout their care journey.
The collaboration will also introduce neurodevelopmental services in phases, beginning with telemedicine consultations in Dubai. Drawing on Re Health’s established expertise, these services will support the assessment and management of conditions including attention-deficit/hyperactivity disorder (ADHD) and autism, broadening access to specialist brain and mind health services.
Dr. Moza Ajaif Al Zaabi, CEO of Mubadala Health Dubai, said: “People experiencing changes in memory or cognition need timely answers and a clear route to appropriate care. Through this collaboration, we are bringing specialist assessment, diagnostics and treatment planning together within MHD’s multidisciplinary setting. This will help patients and families access coordinated care closer to home and give referring physicians a clearer pathway to specialist support.”
The service will initially focus on memory concerns, cognitive impairment, Alzheimer’s disease and other neurodegenerative conditions. Patients will begin with a specialist consultation and clinical assessment. Where clinically appropriate, the care team may recommend further investigations, including blood tests, magnetic resonance imaging (MRI), amyloid positron emission tomography (PET) imaging, cerebrospinal fluid analysis, or genetic testing. Results will inform an individualized care plan based on each patient’s diagnosis, medical history, and eligibility.
Dr. Laila Abdelwareth, CEO of Tawam Molecular Imaging Centre, said: “TMIC’s molecular imaging capabilities will play an important role in supporting accurate diagnosis and treatment planning for patients in Al Ain and the wider Abu Dhabi region. By connecting these capabilities with MHD’s clinical infrastructure and Re:Cognition Health’s specialist expertise, we are building a more connected model of memory and brain health care across the UAE.”
Dr. J. Emer MacSweeney, CEO and Co-Founder of Re:Cognition Health, said: “Launching our first regional clinical service with MHD and TMIC allows us to bring specialist brain and mind health expertise to patients in the UAE through established local facilities. Together, we can support earlier assessment, accurate diagnosis, evidence-based treatment, and ongoing guidance for families. Our aim is to build a service that responds to individual needs while contributing to stronger specialist care in the region.”
Re:Cognition Health brings more than 15 years of experience in assessing and treating cognitive, neurodegenerative, and neurodevelopmental conditions. Its multidisciplinary teams work across neurology, neuroradiology, neuropsychology, psychiatry, and related specialties, with a focus on early and accurate diagnosis, evidence-based treatment, and clinical research.
The collaboration supports M42’s commitment to expanding access to specialized, evidence-based care and strengthening prevention, diagnosis, and treatment pathways across the UAE.
– Ends –
About Tawam Molecular Imaging Centre
Tawam Molecular Imaging Centre (TMIC), part of M42, is a specialist molecular imaging provider delivering advanced PET/CT services in Al Ain and Abu Dhabi. Established to expand access to advanced imaging diagnostics across the emirate, TMIC brings together specialist clinical expertise, advanced imaging technology and integrated radiopharmaceutical capabilities across oncology, cardiology and neurology. TMIC is the only molecular imaging centre in the Middle East and North Africa offering Cardiac PET imaging.
TMIC operates an integrated model that connects PET/CT imaging with on-site radiopharmaceutical production and quality control, supporting a coordinated molecular imaging pathway for patients and referring physicians. Its clinical portfolio includes precision oncology, prostate cancer and neuroendocrine tumour imaging, cardiac PET/CT, and neurodegenerative and dementia imaging. TMIC is accredited by Joint Commission International and operates under the regulatory oversight of the Federal Authority for Nuclear Regulation and the Department of Health – Abu Dhabi. It is also an American Heart Association Training Location.
About Mubadala Health Dubai
Mubadala Health Dubai is a specialty clinic and day surgery center. Established in 2022, it is the first of M42’s strategic expansions outside of Abu Dhabi. It provides comprehensive diagnostic services with international standards for adults and children and a continuum of care for communities in Dubai.
Located in Sunset Mall, Jumeirah 3, Mubadala Health Dubai brings a multidisciplinary model of care delivered through a western-board certified medical team from over 30 clinical specialties.
The 125,000-square foot state-of-the-art facility includes medical and pediatric specialty clinics, a day surgery center, 96 consultation rooms, four operating rooms, two endoscopy suites, as well as an in-house laboratory, in-house pharmacy, a radiology department, dedicated rehabilitation gyms, and dedicated procedure rooms. It also offers a one-of-a-kind post-operative lounge where patients receive comprehensive education from the multidisciplinary team after surgery to optimize their discharge.
About Re:Cognition Health
Re:Cognition Health is an award-winning specialist cognitive healthcare provider headquartered in London, United Kingdom, with over 15 years of experience in the diagnosis, treatment and care of people living with cognitive impairment, Alzheimer’s disease and other neurodegenerative condition; brain injury and neurodevelopmental condictions affecting brain and mind health. Established in 2011, Re:Cognition Health has grown from its first London clinic into an international network, spanning five clinics across Europe and four centres in the United States. The organisation is recognized for its specialist clinical expertise, advanced diagnostic pathways and commitment to innovation in brain and mind health.
Re:Cognition Health is an international leader in clinical research, collaborating with global pharmaceutical research companies on international clinical trials and emerging treatments for Alzheimer’s disease and other brain and mind conditions in children and adults, through its multidisciplinary teams combining expertise across neurology, neuroradiology, neuropsychology, psychiatry and related specialties, with a strong focus on early and accurate diagnosis, evidence-based treatment and advancing innovation in cognitive healthcare.
Tasneem Himid Burhan Himid
Digital Account Executive
mobile: +31 6 82 06 27 10
Edelman Netherlands Keizersgracht 617, 1017 DS, Amsterdam
www.edelman.com